Advances in Therapy

, Volume 27, Issue 5, pp 285–296

Castration-refractory prostate cancer: New drugs in the pipeline

Review

DOI: 10.1007/s12325-010-0038-1

Cite this article as:
Schrijvers, D., Van Erps, P. & Cortvriend, J. Adv Therapy (2010) 27: 285. doi:10.1007/s12325-010-0038-1

Abstract

The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.

Keywords

castration-refractory prostate cancerdocetaxelcabazitaxelabiraterone acetateangiogenesis modulatorsvaccines

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Dirk Schrijvers
    • 1
  • Peter Van Erps
    • 2
  • Jim Cortvriend
    • 2
  1. 1.Department of Hemato-OncologyZiekenhuisnetwerk Antwerpen-MiddelheimAntwerpBelgium
  2. 2.Department of UrologyZiekenhuisnetwerk Antwerpen-MiddelheimAntwerpBelgium